New Thread

Ctrl

⇧

P

Biora Therapeutics, Inc. Stock Price: Quote, Forecast, Splits & News (BIOR)

/

Company Profile

Predictive Oncology Inc. Price & Performance (POAI)

Stock Performance

Updated Mar 26, 2:31 PM UTC

POAI:NASDAQ

$1.46USD

13.61% · $0.23

Open

$1.67

High

$1.65

Low

$1.44

Market Cap

$10.53M

P/E Ratio

-0.5

Volume

2.18M

Year High

$3.06

Year Low

$0.55

What's Happening

Related

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

OverviewOverview
News & Market InsightsNews & Market Insights
PeersPeers
Recent TranscriptsRecent Transcripts
RelatedRelated
EarningsEarnings
Income StatementIncome Statement
Cash FlowCash Flow
Balance SheetBalance Sheet

Recent Transcripts

Phase 1 clinical trial for BT600 showed promising results in ulcerative colitis treatment.

Phase 1 Results

Pharma Partnerships

Active Discussions

BT600 clinical trial shows promise for UC treatment with lower toxicity.

BT600 clinical trial shows promising results for ulcerative colitis drug delivery.

Promising Results

News & Market Insights

Cutera Inc. Seeks Bankruptcy Protection with Debt Plan
Mar 5, 2025
Cutera Inc., a skin care and beauty tech company, has filed for Chapter 11 bankruptcy in Texas. The firm, burdened by $429 million in debt, proposes a prepackaged debt-swap plan worth $400 million to restructure its finances and continue operations.1
Biora Therapeutics to Reveal Quarterly Earnings Amid Challenges
Mar 18, 2025
Biora Therapeutics is set to disclose its quarterly earnings on March 25. Analysts predict a loss of $3.30 per share and minimal revenue of $0.23 million. The clinical-stage biotech firm faces significant financial pressures, with its stock trading near historic lows.2

Go Deeper

How will the recent asset sale to BT BidCo LLC impact Biora Therapeutics' future operations and financial stability?
What are the implications of Biora Therapeutics' delisting from Nasdaq and transition to OTC trading for investors?
How might Biora's Chapter 11 sale process and debtor financing affect its ability to continue developing the BioJet and NaviCap platforms?
What are the potential outcomes of Biora's collaboration with AstraZeneca on the BioJet platform for systemic oral drug delivery?
Could the approval for a larger clinical trial of BT-600 for ulcerative colitis patients revive investor confidence in Biora Therapeutics?

Earnings

Report Date

—

Rev Estimate

—

Avg 1d Change

4.6%

Report Period

Q4 2024

EPS Estimate

—

Implied Move 1d

—

Transcript

Event starts on April 3, 2025 at 4:30 PM UTC

Key Insights

No earnings data available for this event.